Dasatinib In Combination With Trastuzumab And Paclitaxel In First Line Treatment Of Her2-Positive MBC Patients
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Dasatinib|DRUG: Trastuzumab|DRUG: Paclitaxel
Sponsor: Spanish Breast Cancer Research Group
Collaborators: Bristol-Myers Squibb